WO2006094246A3 - N-arylmethyl benzamide sirtuin modulators - Google Patents

N-arylmethyl benzamide sirtuin modulators Download PDF

Info

Publication number
WO2006094246A3
WO2006094246A3 PCT/US2006/007773 US2006007773W WO2006094246A3 WO 2006094246 A3 WO2006094246 A3 WO 2006094246A3 US 2006007773 W US2006007773 W US 2006007773W WO 2006094246 A3 WO2006094246 A3 WO 2006094246A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
sirtuin
disorders
arylmethyl
benzamide
Prior art date
Application number
PCT/US2006/007773
Other languages
French (fr)
Other versions
WO2006094246A2 (en
Inventor
Michael Milburn
Jill Millne
Karl D Normington
Original Assignee
Sirtris Pharmaceuticals Inc
Michael Milburn
Jill Millne
Karl D Normington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc, Michael Milburn, Jill Millne, Karl D Normington filed Critical Sirtris Pharmaceuticals Inc
Publication of WO2006094246A2 publication Critical patent/WO2006094246A2/en
Publication of WO2006094246A3 publication Critical patent/WO2006094246A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
PCT/US2006/007773 2005-03-03 2006-03-03 N-arylmethyl benzamide sirtuin modulators WO2006094246A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65871205P 2005-03-03 2005-03-03
US60/658,712 2005-03-03
US71034905P 2005-08-22 2005-08-22
US60/710,349 2005-08-22

Publications (2)

Publication Number Publication Date
WO2006094246A2 WO2006094246A2 (en) 2006-09-08
WO2006094246A3 true WO2006094246A3 (en) 2006-12-14

Family

ID=36616963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007773 WO2006094246A2 (en) 2005-03-03 2006-03-03 N-arylmethyl benzamide sirtuin modulators

Country Status (1)

Country Link
WO (1) WO2006094246A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064902A2 (en) * 2005-12-02 2007-06-07 Sirtris Pharmaceuticals, Inc. Mass spectrometry assays for acetyltransferase/deacetylase activity
US8685970B2 (en) 2008-05-01 2014-04-01 GlaxoSmithKline, LLC Quinolines and related analogs as sirtuin modulators
WO2010003048A1 (en) 2008-07-03 2010-01-07 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
WO2010037127A1 (en) 2008-09-29 2010-04-01 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
JP2012511048A (en) 2008-12-08 2012-05-17 ノースウェスタン ユニバーシティ Method for modifying HSF-1
WO2011044327A1 (en) * 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
CA2779303A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
MX2013015274A (en) 2011-06-24 2014-03-31 Amgen Inc Trpm8 antagonists and their use in treatments.
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2014182673A1 (en) * 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
WO2014182688A1 (en) * 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204282B1 (en) * 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
WO2003011219A2 (en) * 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2003061566A2 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
US20050222203A1 (en) * 2003-02-11 2005-10-06 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204282B1 (en) * 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
WO2003011219A2 (en) * 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2003061566A2 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
US20050222203A1 (en) * 2003-02-11 2005-10-06 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"enamine screening library", 2006, ENAMINE, 23 ALEXANDRA MATROSOVA STREET KIEV 01103 *
AXEL COUTURE ET AL: "A Simple, Convenient and General Method for the Synthesis of N-Acylalkylaminomethyl- and N-Acylalkylamino(alkyl, aryl, heteroaryl)methylphosphonates and -phosphines Oxides", SYNTHESIS, vol. 9, 1994, pages 953 - 956, XP002391058 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; RODIONOV, V. M. ET AL: "Some reactions of .beta.-(1-naphthyl)-.beta.-alanine and N-methyl-.beta.-(1-naphthyl)-.beta.-alanine", XP002392754, retrieved from STN Database accession no. 1957:9286 *
DATABASE CHEMCATS chemical abstracts service, columbus, ohio, us; XP002392755 *
EL-NAGGAR ET AL: "SYNTHESIS OF SOME ISONICOTINOYL- ANDNICOTINOYL-SULPHONYLAMINO ACID DERIVATIVES AND THEIR ANTIMICROBIAL ACTIVITY", FARMACO ED. SCI., vol. 40, no. 10, 1985, pages 786 - 794, XP009069740 *
IZVESTIYA AKADEMII NAUK SSSR, SERIYA KHIMICHESKAYA 578-82 CODEN: IASKA6; ISSN: 0002-3353, 1956 *
J.V.N. VARA PRASAD ET AL: "2,2'-Dithiobisbenzamides Derived from alpha-, beta- and gamma-Amino Acids Possessing Anti-HIV Activities: Synthesis and Structure-Activity Relationship", BIOORG. MED. CHEM., vol. 6, no. 10, 1998, pages 1707 - 1730, XP002391060 *
M. DESHMUKH ET AL: "A CONVENIENT FAMILY OF CHIRAL SHIFT REAGENTS FOR MEASUREMENT OF ENANTIOMERIC EXCESSES OF SULFOXIDES", TETRAHEDRON LETTERS, vol. 25, no. 32, 1984, pages 3467 - 3470, XP002391055 *
MICHAEL J. STOCKS ET AL: "Structure-driven HtL: Design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity", BIOORG. MED. CHEM. LETT., vol. 15, no. 14, 2005, pages 3459 - 3462, XP002391059 *
PENG HUI ET AL: "Identification of Novel Inhibitors of BCR-ABL Tyrosine Kinase via Virtual Screening", BIOORG. MED. CHEM. LETT., vol. 13, no. 21, 2003, pages 3693 - 3699, XP002391056 *
PORCU M ET AL: "The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 26, no. 2, February 2005 (2005-02-01), pages 94 - 103, XP004727629, ISSN: 0165-6147 *
WU JIN-MING ET AL: "Synthesis and cytoxiticity of artemisinin derivatives containing cyanoarylmethyl group", EUR. J. MED. CHEM. CHIM. THER., vol. 36, no. 5, 2001, pages 469 - 480, XP002391057 *

Also Published As

Publication number Publication date
WO2006094246A2 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
WO2006094209A3 (en) N-benzimidazolylalkyl-substituted amide sirtuin modulators
WO2006094210A3 (en) Tetrahydroquinoxalinone sirtuin modulators
WO2008156869A3 (en) Sirtuin modulating thiazolopyridine compounds
WO2006094246A3 (en) N-arylmethyl benzamide sirtuin modulators
MY149316A (en) Sirtuin modulating imidazohiazole compounds
WO2007019344A8 (en) Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
WO2010037127A8 (en) Chromenone analogs as sirtuin modulators
WO2006078941A3 (en) Novel sirtuin activating compounds and methods of use thereof
MY160006A (en) Thiazolopyridine sirtuin modulating compounds
MX2010004965A (en) Amide derivatives as sirtuin modulators.
WO2006105440A3 (en) Nicotinamide riboside and analogues thereof
MX2011006084A (en) Isoindolinone and related analogs as sirtuin modulators.
MX2011006475A (en) Phthalazinone and related analogs as sirtuin modulators.
MX2010012961A (en) Imidazopyridine and related analogs as sirtuin modulators.
WO2009061453A8 (en) Solubilized thiazolopyridines
IN2012DN03799A (en)
WO2008100376A3 (en) Truncation variants of sirt1 and methods of use thereof
WO2007102861A3 (en) Modulators of cdc2-like kinases (clks) and methods of use thereof
MX2011009213A (en) 8-substituted quinolines and related analogs as sirtuin modulators.
WO2014186313A8 (en) Substituted bridged urea analogs as sirtuin modulators
EA201170137A1 (en) BENZIMIDAZLES AND RELATED ANALOGUES AS SIRTUIN MODULATORS
WO2009085226A3 (en) Inhibitors of cdc2-like kinases (clks) and methods of use thereof
WO2016081692A3 (en) Substituted bridged urea analogs as sirtuin modulators
CY1113732T1 (en) IMIDAZOLO [2,1-B] THIAZOLOGICAL PRODUCTS AS REGULATORS OF SYRTUIN COMPOUNDS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06737003

Country of ref document: EP

Kind code of ref document: A2